Compare BBCP & PACB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BBCP | PACB |
|---|---|---|
| Founded | 1983 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Engineering & Construction | Biotechnology: Laboratory Analytical Instruments |
| Sector | Consumer Discretionary | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 529.1M | 521.8M |
| IPO Year | 2017 | 2010 |
| Metric | BBCP | PACB |
|---|---|---|
| Price | $9.08 | $1.83 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 8 |
| Target Price | ★ $13.50 | $2.40 |
| AVG Volume (30 Days) | 131.8K | ★ 14.5M |
| Earning Date | 09-03-2026 | 11-04-2026 |
| Dividend Yield | ★ 5.70% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.07 | N/A |
| Revenue | ★ $392,867,000.00 | $93,468,000.00 |
| Revenue This Year | $9.73 | N/A |
| Revenue Next Year | $5.12 | $16.01 |
| P/E Ratio | $130.29 | ★ N/A |
| Revenue Growth | N/A | ★ 3.04 |
| 52 Week Low | $5.56 | $1.07 |
| 52 Week High | $12.19 | $3.44 |
| Indicator | BBCP | PACB |
|---|---|---|
| Relative Strength Index (RSI) | 40.34 | 46.58 |
| Support Level | $8.89 | $1.76 |
| Resistance Level | $9.64 | $2.73 |
| Average True Range (ATR) | 0.31 | 0.28 |
| MACD | -0.07 | -0.07 |
| Stochastic Oscillator | 29.03 | 10.53 |
Concrete Pumping Holdings Inc is a provider of concrete pumping services and concrete waste management services in the fragmented United States and United Kingdom markets. Its large fleet of specialized pumping equipment and trained operators enables it to deliver concrete placement solutions. The company's operating segments include U.S. Concrete Pumping, U.K. Operations, and U.S. Concrete Waste Management Services, with the majority of revenue generated from the U.S. Concrete Pumping segment. Geographically, it operates in the United States and the United Kingdom, generating majority of its revenue from the United States.
Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Europe Middle East, and Africa and Asia-Pacific.